The triple-agonist hypothesis: one molecule, three receptor pathways

A researcher's overview of how retatrutide is designed to engage GLP-1, GIP and glucagon receptors simultaneously, and why that makes it a focus of ongoing investigational study.

Overview

This Knowledge Centre article summarises the published research and practical guidance on this topic for laboratory settings. It is reviewed by our editorial team and provided strictly for informational purposes — it is not medical advice.

Key points

• Written for researchers working with lyophilised peptide material.
• Grounded in the peer-reviewed literature listed on our References page.
• Reviewed under our Medical Review Process.

Full article content can be added or edited in the WordPress editor.